Key Sessions
Patrizio Mattei, PhD
Discovery of Zosurabalpin
F. Hoffmann-La Roche Ltd.
Late Breaking Keynote
Claudia Höbartner, Ph.D.
Discovery of RNA-modifying Ribozymes
University of Würzburg
Stanley Crooke, MD, PhD
n-Lorem Foundation: A Dream of Hope and Treatment for Nano-rare Patients Being Realized
n-lorem Foundation
Karina Thorn, PhD
How Novo Nordisk is Expanding our Technology Platforms Via Strategic Internal and External Investments
Novo Nordisk
Jesper Lau, PhD
Designing the Once-Weekly and Oral GLP-1 Semaglutide
Novo Nordisk A/S
Pre-Conference Workshops (am) & Main Conference Day 1 Plenary (pm) - CET (Central European Time, GMT+01:00)
Pre-Conference Workshops (am) & Main Conference Day 1 Plenary (pm) - CET (Central European Time, GMT+01:00)
08:30 - 09:0030 mins
Registration and Coffee
Optional Pre-Conference Morning Workshops: 9.00am-12.00pm
09:00 - 12:00180 mins
Workshop #1: Synthesis, CMC and Characterization of Long and Complex Oligonucleotides
Synthesis, CMC and Characterization of Long and Complex Oligonucleotides
- Thomas Rupp - Managing Director, Axolabs Berlin GmbH
- Chris Oswald - Founder, Owner, and Principal Consultant, Coswald Consulting LLC
09:00 - 09:055 mins
Workshop #2: Unlocking Insights: CMC, Quality & Regulatory - A Case Study on Best Practices and Manufacturing Lessons Learned from Sequence to IND for a Gene Editing Program
Workshop Co-Moderators’ Welcome and Opening Remarks
- Judy Carmody, Ph.D. - Founder and Principal Consultant, Carmody Quality Solutions, LLC
- Melanie Cerullo - Cheif Quality & Regulatory Officer, ReciBioPharm
09:00 - 09:055 mins
Workshop #3: Peptide Therapeutics 2.0: Design and Properties of New and Improved Peptides
Workshop Moderators’ Welcome and Opening Remarks
- Bruce Morimoto, PhD - Vice President, Drug Development, Alto Neuroscience
- Alastair Hay, Ph.D. - Vice President, Peptides, Almac
09:05 - 10:2075 mins
Workshop #2: Unlocking Insights: CMC, Quality & Regulatory - A Case Study on Best Practices and Manufacturing Lessons Learned from Sequence to IND for a Gene Editing Program
CMC Strategies to Accelerate Development Whilst Not Sacrificing Quality
- Judy Carmody, Ph.D. - Founder and Principal Consultant, Carmody Quality Solutions, LLC
09:05 - 09:4035 mins
Workshop #3: Peptide Therapeutics 2.0: Design and Properties of New and Improved Peptides
Plants as Biofactories to Produce Therapeutic Peptides
- David Craik, PhD - Professor of Biomolecular Structure, University of Queensland
09:40 - 10:1535 mins
Workshop #3: Peptide Therapeutics 2.0: Design and Properties of New and Improved Peptides
Fragment-based Approaches for Chemo-enzymatic Peptide Synthesis
- Anna Koijen, PhD - Principal Scientist, EnzyTag B.V.
10:15 - 10:4530 mins
Workshop #3: Peptide Therapeutics 2.0: Design and Properties of New and Improved Peptides
Networking Refreshment Break
10:20 - 10:4525 mins
Workshop #2: Unlocking Insights: CMC, Quality & Regulatory - A Case Study on Best Practices and Manufacturing Lessons Learned from Sequence to IND for a Gene Editing Program
Networking Refreshment Break
10:45 - 12:0075 mins
Workshop #2: Unlocking Insights: CMC, Quality & Regulatory - A Case Study on Best Practices and Manufacturing Lessons Learned from Sequence to IND for a Gene Editing Program
A Case Study on Best Practices and Manufacturing Lessons Learned from Sequence to IND for a Gene Editing Program
- Melanie Cerullo - Cheif Quality & Regulatory Officer, ReciBioPharm
10:45 - 11:2035 mins
Workshop #3: Peptide Therapeutics 2.0: Design and Properties of New and Improved Peptides
Modernising Peptide Manufacture: Keeping Pace with Peptide Therapeutics Innovation
- Alastair Hay, Ph.D. - Vice President, Peptides, Almac
11:20 - 11:5535 mins
Workshop #3: Peptide Therapeutics 2.0: Design and Properties of New and Improved Peptides
Access to Protein Therapeutics by Protein Semi-Synthesis
- Christian Becker, Ph.D. - Professor and Head of the Institute of Biological, University of Vienna
11:55 - 12:005 mins
Workshop #3: Peptide Therapeutics 2.0: Design and Properties of New and Improved Peptides
Closing Remarks
12:00 - 13:0060 mins
Luncheon Spotlight Presentation 1
Amidite RSM Impurity Control and Impact on Oligonucleotide API Quality
- William Fang - Vice President of Oligonucleotide and Peptide Development, WuXi TIDES
12:00 - 13:1070 mins
Luncheon Spotlight Presentation 2
ST Pharm’s Journey from Nucleoside Chemistry to CRISPR Cas
- Youme Gim - Team Leader, Oligonucleotide CDMO I, ST Pharm
13:10 - 13:155 mins
Keynote Sessions - MAIN CONFERENCE
Chairperson’s Remarks
- Yogesh Sanghvi, PhD - President, Rasayan Inc.
13:15 - 13:4530 mins
Keynote Sessions - MAIN CONFERENCE
Discovery of RNA-modifying Ribozymes
- Claudia Höbartner, Ph.D. - Professor of Organic Chemistry, University of Würzburg
13:45 - 14:1530 mins
Keynote Sessions - MAIN CONFERENCE
How Novo Nordisk is Expanding our Technology Platforms Via Strategic Internal and External Investments
- Karina Thorn, PhD - Corporate VP and Head of Research, Global Nucleic Acid Therapies (GNAT), Novo Nordisk
14:15 - 15:0045 mins
Keynote Sessions - MAIN CONFERENCE
Designing the Once-Weekly and Oral GLP-1 Semaglutide
- Jesper Lau, PhD - Vice President, Digital Science & Innovation, Novo Nordisk A/S
15:00 - 15:3030 mins
Networking Refreshment Break in Poster and Exhibit Hall
15:30 - 16:0030 mins
Keynote Sessions - MAIN CONFERENCE
Discovery of Zosurabalpin
- Patrizio Mattei, PhD - Expert Scientist, Medicinal Chemistry, F. Hoffmann-La Roche Ltd.
16:00 - 16:3030 mins
Keynote Sessions - MAIN CONFERENCE
Late Breaking Keynote
16:30 - 17:0030 mins
Keynote Sessions - MAIN CONFERENCE
n-Lorem Foundation: A Dream of Hope and Treatment for Nano-rare Patients Being Realized
- Stanley Crooke, MD, PhD - Founder and CEO, n-lorem Foundation
17:00 - 18:3090 mins
Networking Reception in Poster and Exhibit Hall
18:30 - 18:355 mins
Close of Day One
* 活動內容有可能不事先告知作更動及調整。